......Clinical Trial Patients - Diltiazem

Found a good website that has some really handy information?  Post your links here...

Return to References, Websites, Facts...

Re: ......Clinical Trial Patients - Diltiazem

Postby Savaici » 02 Jul 2013, 11:58

Thanks for locating this. It is a trial of the new Diltiazem topical cream/ointment by the name of VEN 307 that is still not approved by the US Food and Drug Administration, but it is a good thing that it is going through trials now in the USA.
Diltiazem cream (VEN 307)
[info from Ventrus Biosciences @ http://www.ventrusbio.com/content/pipeline.html]
A topical treatment for the relief of pain associated with anal fissures.
Anal fissures are small tears or cuts in the skin that lines the anus. They can be extremely painful, cause bleeding and often require surgery, which itself can have unsatisfactory outcomes. We estimate that there are currently up to 4.3 million cases in the U.S. At present, we are not aware of any FDA-approved drugs for the treatment of pain associated with anal fissures. Diltiazem cream, however, is currently used as the preferred treatment by many gastroenterologists across the U.S. in a version that must be specially mixed, or compounded, for each patient in the pharmacy. When applied topically for the treatment of anal fissures, diltiazem, a drug that has been used for decades for hypertension and angina, dilates the blood vessels supplying the region, reduces anal sphincter tone, and thereby substantially decreases pain. In the majority of multiple clinical trials conducted against placebo or topical nitroglycerin, another commonly used but not FDA-approved treatment, topical nitroglycerin, diltiazem cream significantly reduced the pain associated with anal fissures. Applied topically in our proprietary formulation, diltiazem yields lower blood levels, at less than one-tenth the amount of the lowest dose used for cardiovascular treatment and yet has a considerably greater effect on sphincter tone than diltiazem taken orally. If VEN 307 is approved, we believe we have the potential to capture immediate market share due to the familiarity of gastroenterologists with the current use of diltiazem to treat anal fissures, and its ease of prescription as a pre-formulated FDA-approved product, with no need for compounding necessary at the pharmacy.
We have licensed the exclusive North American rights to VEN 307 for the topical treatment of anal fissures from S.L.A. Pharma AG, who began a Phase III clinical trial in the E.U. in November 2010.
User avatar
Posts: 3797
Topics: 220
Joined: 03 Feb 2011, 17:00
Has thanked: 170 times
Been thanked: 250 times
Gender: Female

  • Similar Topics
    Last post

Return to References, Websites, Facts...

Who is online

Users browsing this forum: No registered users and 0 guests